Literature DB >> 16236444

Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.

Liqun Yu1, Michael A Schwarzschild, Jiang-Fan Chen.   

Abstract

Adenosine A(2A) receptor (A(2A)R) antagonists, including the non-specific adenosine antagonist caffeine, have been proposed as a novel, non-dopaminergic treatment strategy for Parkinson's disease (PD). However, the long-term interaction between caffeine and L-dopa treatment in PD models has not been characterized. We examined the interaction between caffeine and L-dopa following a repeated treatment paradigm in hemiparkinsonian mice. In contrast to the progressively sensitized rotational behavior induced by daily L-dopa (2.0 mg/kg) treatment, tolerance for the rotational response to daily caffeine (2.5 or 10 mg/kg) treatment tended to develop over several weeks. However, after a subsequent two-week washout, challenge with same drug demonstrated an extinction of the sensitized L-dopa-induced rotation, but a sensitization of the caffeine-induced rotation. In a cross-challenge paradigm, daily treatment of mice with L-dopa (compared to daily saline) produced a three-fold enhancement in the rotational response to a subsequent re-challenge with caffeine. Similarly, daily treatment of mice with caffeine produced a six-fold enhancement in the rotational response to a subsequent re-challenge with L-dopa. Furthermore, daily co-administration of caffeine plus L-dopa produced enhanced rotational behavior, compared to caffeine or L-dopa alone, indicating an additive or synergistic interaction between caffeine and L-dopa during repeated treatment. Cross-sensitization between caffeine and L-dopa following repeated treatment and their positive interaction during chronic co-adminstration in hemiparkinsonian mice suggest that repeated exposure to caffeine may alter L-dopa responses in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236444     DOI: 10.1016/j.neulet.2005.09.036

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.

Authors:  John E Kelsey; Nicole A Langelier; Brad S Oriel; Catherine Reedy
Journal:  Psychopharmacology (Berl)       Date:  2008-09-13       Impact factor: 4.530

2.  Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.

Authors:  Danqing Xiao; Jared J Cassin; Brian Healy; Thomas C Burdett; Jiang-Fan Chen; Bertil B Fredholm; Michael A Schwarzschild
Journal:  Brain Res       Date:  2010-09-07       Impact factor: 3.252

3.  Caffeine for treatment of Parkinson disease: a randomized controlled trial.

Authors:  Ronald B Postuma; Anthony E Lang; Renato P Munhoz; Katia Charland; Amelie Pelletier; Mariana Moscovich; Luciane Filla; Debora Zanatta; Silvia Rios Romenets; Robert Altman; Rosa Chuang; Binit Shah
Journal:  Neurology       Date:  2012-08-01       Impact factor: 9.910

4.  Winning a won game: caffeine panacea for obesity syndemic.

Authors:  M Myslobodsky; A Eldan
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

5.  Caffeine Protects Dopaminergic Neurons From Dopamine-Induced Neurodegeneration via Synergistic Adenosine-Dopamine D2-Like Receptor Interactions in Transgenic Caenorhabditis elegans.

Authors:  Rafael V M Manalo; Paul M B Medina
Journal:  Front Neurosci       Date:  2018-03-07       Impact factor: 4.677

Review 6.  Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.

Authors:  Giovanni Schepici; Serena Silvestro; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 5.923

7.  Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.

Authors:  Chih W Hsu; Chin S Wang; Ted H Chiu
Journal:  J Biomed Sci       Date:  2010-01-15       Impact factor: 8.410

8.  Potential Role of Caffeine in the Treatment of Parkinson's Disease.

Authors:  Mohsin H K Roshan; Amos Tambo; Nikolai P Pace
Journal:  Open Neurol J       Date:  2016-07-26

Review 9.  Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.

Authors:  Luiza R Nazario; Rosane S da Silva; Carla D Bonan
Journal:  Front Neurosci       Date:  2017-11-23       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.